Furthering its dedication to working with radiologists to enhance patient care, Qlarity Imaging is a sponsor and exhibitor at RSNA’s Annual Meeting, which is taking place online from November 29 to December 5. Visit the company’s virtual booth to connect with team members via live chat, schedule a meeting, and watch Dr. Newstead demonstrate how a radiologist can use QuantX in a clinical setting.
To view an abstract of the study and download the article in Radiology by Jiang et al, “Artificial Intelligence Applied to Breast MRI for Improved Diagnosis,” click here.
Ad Statistics
Times Displayed: 175489
Times Visited: 3192 For those who need to move fast and expand clinical capabilities -- and would love new equipment -- the uCT 550 Advance offers a new fully configured 80-slice CT in up to 2 weeks with routine maintenance and parts and Software Upgrades for Life™ included.
Indication: QuantX is indicated for the assessment and characterization of breast abnormalities from MRI data in patients presenting for high-risk screening, diagnostic imaging workup, or evaluation of extent of known disease. QuantX is not intended for primary interpretation of digital mammography images.
Risk Information: QuantX is not intended for primary interpretation of digital mammography images. Labeling also provides information to users about potential limitations of the device related to specific subpopulations. For use by licensed healthcare professionals only.
About Qlarity Imaging
Qlarity Imaging assists radiologists in diagnosing breast abnormalities with AI-driven technology that enhances clinical insights. Using quantitative analysis to improve decision making, we provide value to radiologists, health systems, and most importantly patients. Qlarity’s award-winning initial product, QuantX, is the first computer-aided diagnosis software to be cleared by the FDA for breast MRI evaluation. Qlarity Imaging was founded by Paragon Biosciences, a life science innovator that creates, invests in and builds life science companies in artificial intelligence, cell and gene therapy, synthetic biology, and biopharmaceuticals.
About Paragon Biosciences
Qlarity Imaging is a portfolio company of Paragon Biosciences. Paragon is a life science innovator that creates, invests in and builds life science companies in artificial intelligence, cell and gene therapy, synthetic biology and biopharmaceuticals. Our current portfolio includes Castle Creek Biosciences, CiRC Biosciences, Emalex Biosciences, Evozyne, Harmony Biosciences, Qlarity Imaging, Skyline Biosciences, and a consistent flow of incubating companies created and supported by our replicable Paragon Innovation Capital™ model. Paragon stands at the intersection of human need, life science, and company creation.
Back to HCB News
